Evidence map›Paper›PMID 42375628›Full record

ReviewNAM journal2025

New frontiers in anti-cancer drug testing: The need for a relevant In vitro testing model.

Anu Varshini A M, Usha Nandini S, V Ramesh Kumar, Thangam T, Krupakar Parthasarathy

Abstract readReview
In one paragraph

Review in NAM journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Anu Varshini A MDepartment of Biotechnology, Sathyabama Institute of Science and Technology, Chennai, India.
Usha Nandini SDepartment of Biotechnology, Sathyabama Institute of Science and Technology, Chennai, India.
V Ramesh KumarDepartment of Biotechnology, Sathyabama Institute of Science and Technology, Chennai, India.
Thangam TCentre for Drug Discovery and Development, Sathyabama Institute of Science and Technology, Chennai, India.
Krupakar ParthasarathyCentre for Drug Discovery and Development, Sathyabama Institute of Science and Technology, Chennai, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug development is a complex process involving multiple stages, including discovery, preclinical testing and clinical trials to ensure safety and efficacy. In vitro testing is crucial for early-stage anti-cancer drug toxicity and efficacy evaluation, often utilizing traditional monolayer cell cultures. Traditional cell cultures involve growing cells in a two-dimensional monolayer, providing a controlled environment for initial drug testing. It does not entirely replicate or mimic human in vivo microenvironment conditions, where the cell-to-cell interaction and cell-to-matrix (Extra Cellular Matrix) interaction which are vital in cellular function are limited in the traditional cell culture method and the preclinical animal testing models. Also, there are ethical considerations to be faced while using animal models, and the spheroid model can be a potential in vitro model that can reduce the use of animal testing. Hence, the spheroid models, which offer a three-dimensional structure more accurately mimic the natural tumor environment enhancing the study of drug interactions and cellular responses. This review focuses on the various anti-cancer drugs such as 5-Fluorouracil (5-FU), Tirapazamine (TPZ), Cisplatin, Resveratrol, Irinotecan and Doxorubicin that are tested in traditional monolayer cell culture and Spheroid models for comparing the efficacy and toxicity results in both using various analytical methods which helps us understand each method's advantages and limitations in drug development.

Indexed as

Anti-cancer drugsDrug testingSpheroid modelTraditional cell culture

Identifiers

PMID42375628
PMCPMC13312346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.